Vandetanib for Differentiated Thyroid Cancer
Marcia S. Brose, MD, PhD, assistant professor, Abramson Cancer Center, University of Pennsylvania, discusses research into vandetanib for the treatment of patients with differentiated thyroid cancer.
Clinical Pearls
Marcia S. Brose, MD, PhD, assistant professor, Abramson Cancer Center, Department of Otolaryngology, Head & Neck Surgery, Department of Medicine, Division of Hematology/Oncology, Department of Dermatology, University of Pennsylvania, discusses research into vandetanib for the treatment of patients with differentiated thyroid cancer.
- A phase II study randomized 145 patients with locally advanced or metastatic differentiated thyroid carcinoma to vandetanib or placebo
- This study saw fewer full responses than in the DECISION trial, though progression-free survival was 11.1 months compared with 5.9 months in the vandetanib and placebo arm, respectively.
- The vast majority of patients treated with sorafenib will need a second-line therapy, reinforcing the need for an efficacious agent in this space.
Anticipating Novel Options for the RAI-Refractory DTC Armamentarium
May 15th 2023In season 4, episode 6 of Targeted Talks, Warren Swegal, MD, takes a multidisciplinary look at the RAI-refractory differentiated thyroid cancer treatment landscape, including the research behind 2 promising systemic therapy options.
Listen
